Healthcare Industry News: BiO2 Medical
News Release - September 7, 2012
BiO2 Medical Raises $12M in Series C FundingSAN ANTONIO, Sept. 7, 2012 -- (Healthcare Sales & Marketing Network) -- BiO2 Medical, Inc., a Texas based medical device manufacturer with corporate offices in San Antonio, Texas, and R&D and manufacturing operations in Golden, Colorado, has recently secured $12M in Series C funding. The company worked closely with BiO2 Medical's investment bankers, Pasadera Capital for this Series C round. This funding will allow BiO2 Medical to commercialize the Angel™ Catheter. Remeditex Ventures, LLC led the round along with BiO2 Medical's existing investors.
Christopher E. Banas, BiO2 Medical's Chairman and Chief Executive Officer said, "We are thrilled to have Remeditex join on with BiO2 Medical, as they bring a tremendous amount of experience to the company. We are all looking forward to a successful launch of the Angel™ Catheter which will provide a valuable tool for providing PE prophylaxis in critically ill patients."
"We are excited to be part of the highly qualified BiO2 Medical team. BiO2 has developed a promising product that addresses a significant unmet medical need," said John Creecy, Chief Executive Officer and Director of Remeditex Ventures. "We believe the company is poised to become an important innovator, addressing the needs of patients by substantially reducing the risks associated with pulmonary embolism."
BiO2 Medical's Angel™ Catheter, named after its inventor and BiO2 Medical's Chief Medical Officer, Dr. Luis F. Angel, is a central venous catheter and Inferior Vena Cava (IVC) filter combination device, intended to protect against potentially fatal Pulmonary Embolism (PE) in critically ill patients. The Angel™ Catheter will include a first of its kind prophylactic indication for IVC filter use. For more information regarding BiO2 Medical and the Angel™ Catheter, please visit www.bio2medical.com.
Source: BiO2 Medical
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.